Device Trial Radar · NCT07052773
Clinical Evaluation of the Lung Cancer AI-based Decision Support Tool in Low-Dose Lung CT
Last checked: Nov 20, 2026Latest source record: Jul 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Oct 26, 2023
Primary completion
May 5, 2024
Study completion May 5, 2024
Sponsor
- Lead sponsor
- Genesis Medical AINot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 7, 2025
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to clinically validate the accuracy of an AI-based decision support tool-the Lung Cancer Detection System (LCDS)-for detecting lung nodules in asymptomatic adults aged 50-79 with a history of heavy smoking who underwent low-dose chest CT (LDCT) scans. The main questions it aims to answer are: * Can the LCDS accurately detect the presence of solid pulmonary nodules on LDCT scans, as measured by sensitivity and specificity? * How does the LCDS's performance compare to existing AI systems using the Area Under the Curve-Receiver Operating Characteristic (AUC/ROC) Curve? Researchers will compare the AI-based interpretations to a ground truth established by consensus among radiologists' double-readings to see if the LCDS can accurately classify cases as 'lung nodule presence' or 'lung nodule absence'. Participants will: * Have their de-identified LDCT scans (collected between 2018 and 2023) reviewed retrospectively. * Be evaluated through the LCDS tool, which will classify cases based on lung nodule presence. Contribute to performance evaluation using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and ROC analysis.
Conditions
- Lung Cancer Screening
Interventions
Lung Cancer Detection System (LCDS)Device
An AI-based decision support software designed to detect solid pulmonary nodules on LDCT chest scans. In this study, the LCDS is applied retrospectively to 100 previously acquired LDCT scans, and its performance is compared to a ground truth established by double-read radiologist reports with arbitration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of LCDS for Detection of Solid Pulmonary NodulesTime frame: Through study completion, an average of 1 year
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Assuta Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.